Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial.

doi:10.1158/1078-0432.CCR-20-0126

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jan 2021

Guerini-Rocco Elena, Gray Kathryn P, Fumagalli Caterina, Reforgiato Marta Rita, Leone Isabella, Rafaniello Raviele Paola, Munzone Elisabetta, Kammler Roswitha, Neven Patrick, Hitre Erika, Jerusalem Guy, Simoncini Edda, Gombos Andrea, Deleu Ines, Karlsson Per, Aebi Stefan, Chirgwin Jacquie, Di Lauro Vincenzo, Thompson Alastair, Graas Marie-Pascale, Barber Matthew, Fontaine Christel, Loibl Sibylle, Gavilá Joaquín, Kuroi Katsumasa, Müller Bettina, O'Reilly Seamus, Di Leo Angelo, Goldhirsch Aron, Viale Giuseppe, Barberis Massimo, Regan Meredith M, Colleoni Marco

Abstract excerpt

PURPOSE: Women with hormone receptor-positive early breast cancers have a persistent risk of relapse and biomarkers for late recurrence are needed. We sought to identify tumor genomic aberrations associated with increased late-recurrence risk. EXPERIMENTAL DESIGN: In a secondary analysis of Study of Letrozole Extension trial, a case-cohort-like sampling selected 598 primary breast cancers for targeted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Chromosome Aberrations

Share to Genomics

Share to High-Throughput Nucleotide Sequencing

Share to Kaplan-Meier Estimate

Share to Neoplasm Recurrence, Local

Share to Postmenopause

Share to Receptors, Estrogen

Source

Open in PubMed

Identifiers

PMID: 33082214
DOI: 10.1158/1078-0432.CCR-20-0126

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial.PMID 33082214Read ↗

Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.Semantic proximity Read ↗

Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.Semantic proximity Read ↗

Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population.Semantic proximity Read ↗

Comparative Genomic Profiling of Second Breast Cancers following First Ipsilateral Hormone Receptor-Positive Breast Cancers.Semantic proximity Read ↗

Comprehensive genomic evaluation of advanced and recurrent breast cancer patients for tailored precision treatments.Semantic proximity Read ↗

Clinical Genomic Profiling to Identify Actionable Alterations for Very Early Relapsed Triple-Negative Breast Cancer Patients in the Chinese PopulationSemantic proximity Read ↗

Multi-state modeling associates proliferation genes with early estrogen receptor-positive breast cancer recurrence and survivalSemantic proximity Read ↗

Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients.Semantic proximity Read ↗

Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrencesSemantic proximity Read ↗

Comprehensive genomic evaluation of advanced and recurrent breast cancer patients for tailored precision treatmentsSemantic proximity Read ↗

Concordance of genomic alterations between primary and recurrent breast cancer.Semantic proximity Read ↗

Proteogenomics decodes the evolution of human ipsilateral breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.